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1. Introduction
Immunostimulation is fundamental to efficient host responses to pathogens; a comprehensive
understanding of which will inform the development of the next generation of vaccines.
Integral to vaccine development is the mode of delivery to the appropriate host tissue. Mucosal
tissue, with its ability to both tolerise and activate host immune responses, represents an ideal
site for vaccine delivery. The continued study of such mucosal tissue with respect to its ability
to exert immune activation, suppression and in deed deviation, will be of benefit to the design
of next-generation vaccines.
Mucosal immunity is governed by the interaction of the barrier epithelial cells of the mucosal
surface with the underlying immune cells. The most important immune cells, which are
responsible for determining immune responsiveness at these surfaces, are those of the innate
immune system; antigen presenting cells (APCs) such as dendritic cells (DCs) and macro‐
phages (Mϕs). DCs play an important role in antigen processing and presentation, thus
priming antigen-specific effector T cell responses by homing from the challenge site to the local
lymph node. Mϕs, on the other hand, stay within the mucosal tissue at the forefront of the
challenge site and play a major role in immune fate decision: activation, deviation or suppres‐
sion. Under certain genetic, environmental and immunological conditions, these resident
tissue macrophages are rendered dysfunctional and play a pivotal role in establishment and
persistence of pathology. Taking into consideration their tissue residence and their potential
to prime a wide range of immune responses, this review will focus on immunostimulation in
the context of mucosal Mϕ function in both homeostasis and pathology in the oral mucosa and
gastrointestinal tract (GIT). In addition, immunostimulation via Mϕ functionality can only
fully be appreciated by considering the relative relationship of activation with both immune-
deviation and suppression; such functionality will also be considered in this review.
© 2014 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. Macrophages
Macrophages have long since been recognised to play a central role in the immune response.
They are mononuclear phagocytic cells, which have been demonstrated to be involved in
pathogen recognition, clearance, antigen processing and presentation, inflammation and
tissue repair as well as pro-and anti-tumoral responses. Tissue Mϕs perform a range of
important homeostatic functions and exist in many different tissue-specific forms: microglia
in the brain, alveolar Mϕs in the lung, Kupfer cell in the liver, osteoclast in the bone, as well
as splenic, intestinal, bone marrow and lymph node-associated subcapsular sinusoidal/
medullary Mϕs. Thus, Mϕs are central to innate immune inflammatory mechanisms and the
priming of adaptive responses to both intracellular and extracellular pathogens as well as
immune regulation and tumour surveillance; such diversity of effector functionality would
suggest mucosal macrophages to be ideal targets for vaccine therapy.
2.1. Mϕs exhibit distinct functional subsets
In general, Mϕ functions are conferred by environmental stimuli, pre-programming or the
route of differentiation. As such, Mϕs exist in several subsets, which exhibit discrete functional
and phenotypic traits. A certain level of confusion exists however, as to whether the Mϕ subset
has been generated by the use of distinct activation signals or as a consequence of longer-term
culture/differentiation, or is even pre-programmed in the monocytes. There is some evidence
to suggest that monocyte pre-programming is of some functional relevance, where there is a
level of heterogeneity, and monocytes potentially exist as a classical (CD14++CD16-HLA-DR+)
subset and a pro-inflammatory subset (CD14+CD16+HLA-DR++) [1,2] biased towards high level
TNFα production and present in high numbers in inflammatory pathologies [3,4]. In its
simplest guise, Mϕ subsets have been described to exist as two functionally distinct forms, in
particular associated with Th1 or Th2 adaptive responses: a pro-inflammatory subset (classi‐
cally activated, type I or M1) and an anti-inflammatory/regulatory subset (alternative activa‐
tion, type II or M2) [5,6], although further studies have suggested several subdivisions may
exist within the M2 subset (reviewed in [7]).
M1 macrophages, also referred to as classically activated Mϕs, are generally pro-inflammatory
Mϕs, which exhibit a functional phenotype that is anti-microbial (mediating resistance to
intracellular pathogens), tissue destructive and anti-tumoral [8]. Upon activation, these Mϕs
express a plethora of pro-inflammatory cytokines (TNFα, IL-1β, IL-6, IL-12, IL-18, IL-23),
chemokines (CXCL1, 2, 3, 5, 8, 9, 10, CCL2, 3, 4, 5, 11, 17 and 22)[9], proteases and ROS/RNS.
As a consequence of this wide array of cytokines expressed, M1s play a pivotal role, not only
in innate responses, but also adaptive, antigen-specific responses. As M1s secrete a high level
of IL-12, they promote Th1 differentiation, hence cell mediated immune mechanisms for the
defence against intracellular pathogens [10,11]. In addition, Holscher et al., 2001, described the
protective role of IL-12p40; this subunit is also common to IL-23, which is produced by M1s
and is important in the differentiation and activation of Th17 cells [12,13]. Mϕs can be polarised
to the M1 phenotype in the presence of IFNγ and in combination with inflammatory stimuli
such as LPS or TNFα. In addition, this M1 phenotype can also result from differentiation in
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the presence of GM-CSF [14,15] and further polarising signals such as anoxic environments
[16], β-chemokines [17] and phorbol myristate acetate, PMA [18,19]. The presence and
activation of pro-inflammatory M1s would have to be tightly controlled, as over-activation or
dysregulation of M1s may result in uncontrolled pro-inflammatory pathology. The involve‐
ment of such a distinct Mϕ subset has been suggested to be central to the tissue-destructive
pathology associated with the chronic inflammatory bowel disease, Crohn’s disease [20].
In addition to the profile of factors listed in the paragraph above, the general profile of the M1
effector phenotype is IL-10lo IL-12hi IL-23hi [21]. Associated with the M1-polarising stimuli,
IFNγ and LPS, are distinct expression and activation profiles of intracellular signalling
components. M1 polarisation is transduced via the transcription factors STAT-1 and NFkB,
driving the expression of immune mediators characteristic of this subset, and via the activity
of SOCS3 [22]. Finally, the M1-specific transcription factor, STAT-1, has been demonstrated to
inhibit STAT-6 activation; this factor is required for M2 polarisation [23], thus an M1-associated
transcription factor cross-regulates/suppresses M2 polarisation/activation. These observations
alone were suggestive that there was a level of plasticity that existed between M1 pro-
inflammatory Mϕs and the anti-inflammatory/regulatory M2 Mϕs.
M2 macrophages, which are also referred to as alternatively activated Mϕs, were found to
exhibit a functionally distinct phenotype to that of M1s, originally via the ability of IL-4 to
induce MR expression, followed by another Th2 cytokine, IL-13 [24,25]. M2 functionality was
generally described as an anti-inflammatory/immunoregulatory phenotype, which also
mediates tissue remodelling and repair, resistance to parasites and tumour promotion, all of
which was dependent on the activation/differentiation signals encountered [6,26]. Extensive
research has found a wide range of M2 polarising signals to exist: these priming signals include
IL4/IL13, IL-10, TGFβ, M-CSF, Vitamin D3, immune complexes and the Th2-derived cytokine,
IL-21 [27] and reviewed in [28]. The versatility in polarising signals and effector functionality
of M2 Mϕs resulted in the proposal that M2s exist in a variety of subsets: M2a (tissue repair),
M2b (B cell IgG production) and M2c (anti-inflammatory/scavenging mechanisms) (reviewed
in [7,26]) (refer to figure 1 below).
M2 polarisation is induced by a wealth of exogenous factors, presented above, which drive
distinct signalling/transcription factor pathways as well as signature gene expression. There
is an ever-increasing understanding of these endogenous molecular pathways initiated by
polarising factors such as IL-4. Whereas p65 NFκB subunit expression is associated with
M1 polarisation, M2 polarisation has been described to be orchestrated by p50 NFκB [30,
31],  whereby  p50  NFκB  inhibits  NFκB-dependent  M1  polarisation.  In  addition,  p50-
deficient mice exhibit exacerbated M1-driven inflammatory responses with a concomitant
suppression of M2-driven responses (allergy and anti-helminth immunity). In addition to
p50 NFκB, M2-like differentiation/ polarisation has been demonstrated to be induced by
agonists  of  PPARγ [32],  CREB-controlled C/EBPβ [33]  and epigenetic  regulation of  M2-
defining gene products in mice (arginase-1, Ym1, FIZZ1 and mannose receptor) via the IL-4-
STAT6-dependent histone demethylation of H3 by the histone demethylase, jmjd3 [34, 35].
Finally,  signalling  components  not  only  positively  regulate  Mϕ  differentiation  and
activation;  the  generation  of  alternatively  activated  (M2)  Mϕs  has  been  reported  to  be
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Figure 1. Activation and differentiation drive a range of functional macrophage phenotypes Mϕ effector subsets exist
as pro-inflammatory M1 and regulatory or anti-inflammatory M2 phenotypes. M1s are elicited through activation by
LPS and IFNγ and differentiated by GM-CSF, whereas M2s can be subdivided into M2a, M2b and M2c according to
stimulation/differentiation and functional phenotype. Functional phenotype is characterised by a series of molecular
markers listed in the incorporated table under the categories of (1.) signalling molecules, (2.) cytokine expression pro‐
file, (3.) chemokine profile, (4.) scavenger receptor expression and (5.) tryptophan metabolism (inducible nitric oxide
synthase, iNOS, and arginase, Arg) and the poorly defined effector molecules, FIZZ-1 and Ym-1. The overall function of
these Mϕ subsets is summarised in the lower segment of the table, ranging from pro-inflammatory, anti-tumour re‐
sponses to anti-inflammatory, regulatory and tissue reparative responses. This figure is adapted from [28] and infor‐
mation presented in [7, 9, 23, 26, 29].
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repressed  by  the  negative  regulator,  src  homology  2-containing  inositol-5’-phosphatase,
SHIP, a potent negative regulator of the PI3K pathway [36].
2.2. Functional and phenotypic plasticity of macrophages
Tissue-resident macrophages can thus express a wide variety of functional phenotypes, which
is governed by the manner in which they are activated, differentiated or pre-programmed.
This results in potentially two distinct opposing types; pro-inflammatory M1 Mϕ and anti-
inflammatory/regulatory M2 Mϕ. If these subsets represent a terminally differentiated
phenotype, then it is probable that Mϕs are incapable of functional plasticity. What is becoming
clear however, is that M1 and M2 Mϕs do exhibit a level of plasticity and that tissue Mϕs are
more likely represented on an intermediate sliding scale between pro-inflammatory/immune
activatory and anti-inflammatory/regulatory functionality. Indeed, this functional plasticity
and manipulation of Mϕ subset has been observed in many studies. A study focussing on bone
marrow-derived Mϕs, observed that cytokine functional phenotypes could be altered/
reversed in the presence of Th1 or Th2 cytokines and that this plasticity in function was
determined by changes to tissue microenvironment and whether these cytokines were
encountered before or concomitantly with an activation stimulus [37]. This plasticity or
reversal of Mϕ cytokine phenotype has recently been reinforced by the demonstration of a
reversible, bi-directional differentiation of pro-inflammatory (M1) and anti-inflammatory
(M2) monocyte-derived Mϕs in response to GM-CSF and M-CSF [38]. In addition, the control
of these M-CSF and GM-CSF Mϕ and the invading monocyte populations has been demon‐
strated to be controllable via the use of neutralising antibodies to these differentiation factors
in both homeostasis and inflammatory pathology of antigen-induced peritonitis and lung
inflammation [39]. This study suggested that M-CSF-derived Mϕs played a non-reductant
(M2-like regulatory) role whereas GM-CSF Mϕs maintained the inflammatory response (M1-
like pro-inflammatory), contributing to prolonged monocyte and neutrophil infiltration. This
is suggestive of the possibility of in vivo control of Mϕ effector phenotype through reduction
in numbers and manipulation of plasticity.
Macrophage plasticity is not only determined by the differentiation factors but also by the local
environmental stimulation factors, the intracellular signalling molecules activated and by the
effector cytokines expressed/secreted by the macrophages. These environmental factors not
only modulate Mϕ functional plasticity, the Mϕs themselves are able to cross-regulate each
other thus moving or consolidating Mϕ effector response along this sliding scale of function‐
ality between pro-inflammatory and anti-inflammatory/regulatory responses. These exoge‐
nous regulators include M1 and M2-associated cytokines (IFNγ, IL-12, IL-10, IL-4) which cross-
regulate each other and immune complexes (ICs) which, through binding of their respective
FcγR, can revert activation status or suppress/modulate cytokine expression, such as suppress
IL-12 and induce IL-10 to an M2-like phenotype [40,41]. There is a wide range of intracellular
signalling molecules, which play distinct roles in this cross-regulation and plasticity between
M1 and M2 subsets. Pro-M1 responses can be mediated by SHIP-1 [42], p65 NFκB and IRF5
[43]; all of which, suppress M2s. On the flip-side, pro-M2 responses have been demonstrated
to be mediated by tpl-2, p50 NFκB [31], STAT-6 [34], C/EBPβ and c-maf [33]; again, these
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molecules suppress the development of the other canonical Mϕ subset, M1s (reviewed in [44]).
Indeed, the importance of the NFkB signalling pathway has been further consolidated by a
study demonstrating that IKKβ played an anti-inflammatory role by suppressing classical
Mϕ activation/M1 Mϕ phenotype via negative cross-talk with STAT-1, which is involved in
the expression of IL-12, iNOS and MHCII [45] and via the maintenance of the IL-10hi/IL12lo
functional phenotype [46].
Considering Mϕ subset phenotype, its environmental differentiation factors, activatory
stimuli and effector cytokine profile; macrophage responses can be modulated by a wide range
of factors which includes both positive and negative regulators. As such, the potential
involvement of macrophages as an immunotherapeutic target for several pathologies can only
be appreciated by a full understanding of both activatory and regulatory signals: immunosti‐
mulation, immunosuppression and immune deviation.
3. Stimulation and suppression of Mϕ effector responses
Macrophages exhibit a wide variety of receptors, which transduce a multitude of immunosti‐
mulatory signals. These activatory receptors are centred on responsiveness to conserved
broad-spectrum molecular patterns associated with immune responsiveness to pathogens or
endogenous, self-associated, danger signals. Pattern recognition receptors (PRRs) which
stimulate or co-activate immune responses include the toll-like receptors (TLRs), NOD-like
receptors (NLRs), C-type lectin receptors (CLRs) and scavenger receptors (SRs). In addition to
these PRRs, Mϕs can also be activated by immune complex recognition via FcRs and cytokine
stimulation through their cognate receptors.
Toll-like receptors respond to a wide repertoire of PAMPs, expressed on bacterial, viral, fungal
and parasitic pathogens, and DAMPs; generally activating innate inflammatory-or anti-viral
responses through the involvement of discriminatory utilisation of receptors, adaptor proteins
and either NFκB-or IRF-dependent signalling pathways [47]. Indeed, the utilisation of such
signalling pathways, in Mϕ polarisation, make it impossible to totally devolve consideration
of polarisation, activation, cross-regulation and suppression. TLRs are expressed according to
the localisation of pathogens; TLR2 (CD282), TLR1 (CD281), TLR6 (CD286), TLR4 (CD284) and
TLR5 (CD285) being expressed on extracellular membranes, recognise extracellular pathogens,
whereas TLR3 (CD283), TLR7 (CD287), TLR8 (CD288), and TLR9 (CD289) are expressed
intracellularly, associated with endosomal membranes and recognition of intracellular
resident pathogens. The extracellular facing TLRs were found to recognise a range of conserved
PAMPs expressed by bacteria, including lipopeptides, LPS and flagellin, whereas TLRs 3, 7, 8
and 9 recognise dsRNA, dsDNA and hypomethylated CpG DNA motifs, respectively,
expressed by viruses and bacteria.
TLRs activate a range of important signalling pathways and transcription factors, where their
PAMPs activate MAPKs (ERK-1/2, p38 MAPK and JNK), which enhance gene expression and,
in the case of p38, mRNA stability via AU-rich repeats present in the 3’UTRs. Activation of
MAPK-dependent transcription factors along with other transcription factors are responsible
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for a wide repertoire of gene expression and immune functionality. Indeed, activation of TLR4
by LPS has been observed to activate ERK-1/2, JNK and p38 MAPKs as well as NFκB and IRF3;
these signalling pathways give rise to a multitude of immune mediators which include TNFα,
IL-1β, IL-6, IL-8, IL-12, iNOS, IL-10, MHC II. Macrophage activation can thus exhibit a wide
range of functions, which include pro-inflammatory, anti-microbial responses, anti-inflam‐
matory/regulatory responses and priming of adaptive immune responses through their
capacity to process and present antigen.
Taking into consideration the previous sections, LPS and other PAMPs may be able to induce
a wide variety of immune mediators; the expression of which will also be determined by other
activatory stimuli, differentiation factors and both exogenous and endogenous suppressive
molecules. TLR signals can be negatively regulated by a multitude of molecules (reviewed in
[48]) which include; Myd88s, IRAK-M, IRF-4 [49,50], TREM-2, ST2 [51], Tollip, TRIAD3A,
SOCS-1, SOCS-3, SHP1, SHP2, SIGIRR [52]. In addition to endogenous suppressors of TLR
activation signals, it is becoming evident that TLRs can cross-regulate each other, resulting in
suppression of distinct TLR signalling pathway or endotoxin tolerisation of Mϕs through
homo-or hetero-tolerisation of distinct TLRs and their ensuing effector functionality (reviewed
in [53]). Such mechanisms of tolerisation have been demonstrated to be differentially utilised,
dependent on Mϕ subset as well as activation signal [54]. Such complex, inter-twined signal‐
ling pathways enable a level of innate “specificity” of anti-microbial activation response as
well as a way in which these activatory signals are fine-tuned, suppressed or modulated.
NOD-like receptors (NLRs); due to their intracellular expression, originally thought to
specifically respond to intracellular pathogens and their PAMPs, it has become apparent that
NLRs are integral to the innate detection of both extracellular and intracellular-resident
pathogens. The superfamily of NLRs consists of NOD1 and NOD2 which are intracellular
receptors for peptidoglycan (D-γ-glutamyl-meso-DAP and muramyl dipeptide, respectively)
[55]. NOD1 and NOD2 activate NFκB through the recruitment and activation of RIP2 and
resulting activation of the IκB kinase complex [56]. As a result, NOD-signalling can induce
pro-inflammatory, anti-microbial defences via the expression of a wide array of NF-κB-
dependent gene products (reviewed in [57]).
In addition to the NFκB-activating NODs, the NLR family is also made up of a collection of
receptors involved in the activation of caspases [58], specifically caspases 1 and 5 that are
integral for the inflammasome construction, activation and processing of the pro-cytokines
pro-IL-1β and pro-IL-18 into the mature and secretable IL-1β and IL-18. The inflammasome is
activated by extracellular ATP and hypotonic stress, both representative of endogenous danger
signals or DAMPs. ASC is an adaptor protein which recruits caspase-1 into an inflammasome
activation complex; knock-out mice have demonstrated ASC to be essential for LPS-induced
activation of caspase-1, where these mice failed to activate pro-caspase-1 or produce IL-1β and
IL-18, even in the event of stimulation by both LPS and ATP (activation of the P2X7 receptor)
[59]. This requirement for inflammasome-mediated caspase-1 activation, hence IL-1β matu‐
ration and secretion, in response to LPS (a TLR4 ligand), emphasises a collaborative role for
TLR and NLR pathways in the production of IL-1β and the ensuing inflammatory response.
Other NLR family members, NALP1, NALP3 and Ipaf, have all been demonstrated to be
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associated with ASC in the inflammasome, playing an integral role in caspase-1-dependent
activation of pro-inflammatory cytokines [60]. NLRs have also been reported to suppress both
NFκB and caspase activation pathways. With respect to inhibition of NFκB, NALP10 and
NALP12 display a suppressive activity, whereas NALP7 and NALP10 are suppressive for
caspase activation (reviewed in [61]). Again, it is imperative to the direction of Mϕ functional
responses that the expression profile of NLRs be characterised, along with potential cross-
communicating PRRs; this total profile gives scientists an insight of potential control of Mϕ
functionality as being activatory, suppressive or even being able to deviate/modify the cellular
response.
RIG-like receptors (RLRs): are key intracellular innate immune sensors of viral infection.
Whereas the predominant viral PRRs in DCs (particularly pDCs) are TLR3, TLR7, TLR8 and
TLR9, RLR viral sensing and expression is predominant in Mϕs [62]. Currently, the main RLRs
are retinoic acid inducible gene-1 (RIG-1) and melanoma differentiation-associated gene
(MDA)5; both of which detect dsRNA [63,64]. Similar to the viral-sensing TLRs, RLRs activate
NFκB and IRF3 signalling pathways, resulting in gene expression of pro-inflammatory
cytokine genes and anti-viral type I interferons (IFNα and IFNβ). Upon viral infection, these
interferons exhibit a positive feedback loop which up-regulates RLR expression. MDA5 has
been demonstrated to be important in the detection of picornovirus and polyinosine polycy‐
tidylic acid, poly(I:C)-induced IFNα production. On the other hand, the importance of RLRs
to macrophage anti-viral responses is enforced by observations that RNA helicases eg. Lgp2,
inhibits RIG1 signalling [65] and that an evasion mechanism utilised by hepatitis C virus is the
production of RLR signalling inhibitory proteins [66,67]. This overlap in structure/functional
relationships between TLRs and RLRs is suggestive that these receptor types function in
tandem to provide ubiquitous anti-viral protection. Additionally, it is unclear as to whether
RLRs also interact and mediate inflammasome activity, as a study by Johnston et al in 2005,
has shown that a pox virus pyrin domain protein interacts with ASC-1 (NLR family member)
and inhibits inflammatory and apoptotic inflammasome activity [68]. This viral escape
mechanism, targeting NLR-mediated inflammasome activity, is also suggestive that RLRs
cross-communicate with NLRs; thus efficient anti-viral protection is truly a trinity of innate
reception between TLRs, NLRs and RLRs (reviewed in [61]).
Scavenger receptors (SRs) and C-type Lectin receptors (CLRs): this is a large group of
receptors widely expressed on macrophage cells [69] which scavenge pathogenic material and
cellular debris, initiating clearing responses through receptor-mediated endocytosis, phago‐
cytosis or signals inflammatory responses. Responses elicited are dependent on patterns being
recognised and combinations of PRRs being employed. The CLRs, being lectin receptors are
generally sugar receptors, whereas SRs recognise and respond to a wider range of molecular
patterns; however, there is a level of overlap, hence confusion between receptors of these
families. Scavenger receptors are a broad family of PRRs, which involve both opsonin-
mediated phagocytosis and opsonin-independent PRRs; the latter even including TLRs,
lectins, complement receptors (CRs), CD14, CD36, scavengers of ACAMPs (see later section).
Scavenger receptors include the SR-A class of receptors (SR-AI, SR-AII, MARCO), SR-B (CD36,
SR-BI and Croquemort, CD163 – haemoglobin scavenger receptor), SR-C class (dSR-CI) and
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SR-E (LOX-1) as well as other SR-A-like class members (SR-CLI – a potential CLR on the basis
of C-type lectin domain expression), SR-D (macrosialin). In general, these scavenger receptors
recognise a wide range of PAMPs including LTA, LPS, bacterial DNA, whole bacteria, sugar
moieties and DAMPs, thus clearance of dead and dying host tissue, as well as pathogenic
material (reviewed in [70]). The majority of the signalling scavenger receptors (Dectin-1,
Dectin-2, Mϕ Mannose Receptor) are CLRs and will be covered in the next section.
CLRs play a major role in recognition and activation of anti-microbial immunity against a
diverse range of pathogens, which include fungi, bacteria, viruses and parasites. They are
receptors which contain one or more carbohydrate recognition domains (CRDs) which bind a
wide variety of carbohydrate ligand moieties. Generally, CLRs can be categorised as either
having a built-in endogenous signalling activity or requiring interaction with a partner adaptor
protein which possesses signalling activity (reviewed in [71]). CLRs signal via integral ITAMs
or partner ITAM-bearing adaptors such as FcγRs. Integral ITAM-bearing CLRs generally
signal through a syk/CARD9 pathway which ultimately results in NFκB activation; such
signalling CLRs include Dectin-1, Dectin-2 and Mincle. These CLRs are particularly prominent
in mounting anti-fungal responses; Dectin-1 responds to β-glucans expressed in the fungal cell
wall by initiating a variety of cellular responses which include phagocytosis, respiratory burst,
activation of inflammasomes, cytokine production and the polarisation of adaptive responses
to cell mediated immunity mediated by Th1 and Th17 cells. In addition, Dectin-1 exhibits cross-
talk with TLR2 and other myd88-dependent TLRs, thus again, co-operation of PRRs is critical
for tailoring appropriate immune responses (reviewed in [72]). Dectin-2 and Mincle both
recognise fungal α-mannans with Dectin-2 being associated with innate recognition and
induction of Th17 responses. Of particular importance to the recognition and signal activation
in response to fungal infection is the observation that Dectin-2 (signalling) can heterodimerise
with Dectin-3, thus CLRs demonstrate a level of co-operativity with each other and fine-tuning
of their responses to the fungal pathogen [71].
Bacterial sensing utilises Mincle, mannose receptor (MR) and DC-SIGN. MR has been shown
to be involved in the recognition and responsiveness to Klebsiella and Streptococcus sp but so
far, has not been recognised to contain a signalling motif. To initiate antibacterial responses,
it is likely that the MR co-operates with other PRRs. Mincle however signals through the
pathway detailed above, in order to activate NFκB-mediated responses required for innate
and consequent cell mediated immune responses to Mycobacterial infection through recog‐
nition and binding of mycobacterial cord factor, trehalose-6,6’-dimycolate, TDM. Mycobacte‐
ria are also recognised and a response initiated through ManLam (mannosylated
lipoarabinomannan) binding to DC-SIGN which is expressed by DCs; whether this CLR is
expressed by Mϕs is yet to be definitively characterised [71]. DC-SIGN has also been described
as being involved in viral recognition by binding to the gp120 envelope protein of HIV-1; this
mechanism however may be more representative of a mode of viral transmission rather than
anti-viral immunity. CLRs such as CLEC9A (DNGR-1) has been shown to be protective, by
facilitating antigen cross-presentation, hence controlling infection of vaccinia virus and herpes
simplex virus. Finally, both Dectin-2 and MR are involved in immunity to parasites, whereby
Dectin-2 recognises Schistosoma mansonii egg antigen SEA resulting in the activation of the
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NLRP3 inflammasome and alleviating Th2 pathology. Of particular interest is the fact that
Dectin-2 can also promote Th2responsiveness, as opposed to suppressing it, when responding
to the common allergen of house dust mite [71]. MR drives protective Th2 responses during
S.mansonii infection whereas enhances uptake of infectious circariae. These last few observa‐
tions with respect to Dectin-2 and MR and their ability to drive Th2 responses would appear
to conform to the previously observed study of Mills et al, whereby M2 macrophages were
associated with Th2 immunity [5]; indeed, MR at least, has been assigned as an M2 marker. On
the flip-side, Dectin-1 has been associated with initiation of Th1 and Th17 anti-fungal responses;
it would appear that any potential activation and modulation of specific immune responses
would have to consider the role of pathogen associated carbohydrate expression and their
respective CLRs expressed on host macrophages.
Siglecs: sialic acid-binding Ig-like lectins are members of the immunoglobulin superfamily
involved in the recognition and reception of sialylated glycoconjugates, involved in endocy‐
tosis, positive and negative activation signals. Sialic acids are a family of nine-carbon sugars
which are derivatives of neuraminic acid or keto deoxynonulosonic acid and appearing in
different glycosidic linkages, typically at the exposed, non-reducing ends of oligosaccharide
chains attached to proteins and lipids. It is thought that sialic acid residues either, mask sub-
terminal sugars, prevent non-specific cell-cell interactions or act as ligands for modulating
selective cell-cell interactions [73]. Currently, there are 13 Siglec family members expressed in
humans and classified into two distinct subsets; siglecs 1 (CD169), 2 (CD22) and 4 are activatory
receptors whereas siglecs 3 (CD33) and 5 (CD170) to 11, 14 and 16 (CD33-related siglecs) exhibit
suppressive activity through two conserved ITIMs (immunereceptor tyrosine-based inhibition
motif) in the cytoplasmic domain which are responsible for the recruitment of the signal
suppressive phosphatase enzymes SHIP (lipid phosphatise), SHP-1 and SHP-2 (protein
tyrosine phosphatises), which result in raised activation thresholds and antagonism of ITAM-
dependent activation. More recently, tyrosine phosphorylation of CD33 and siglec-7 can
recruit SOCS3 which leads to ubiquitination and proteosomal degredation of the Siglec;
regulation of the negative regulator! [74,75]. Thus, expression and activation of distinct
expression profiles of siglecs can either positively or negatively regulate immune and inflam‐
matory responses. Monocytic cells have been shown to express Siglec-3 (CD33) and Si‐
glecs-5,-7,-9 and-10, whereas generally, Mϕs express sialoadhesin (Siglec-1) and Siglecs-3
and-5 (reviewed in [76]), yet differentiation of monocytes to pro-and anti-inflammatory Mϕs
using GM-CSF and M-CSF, respectively, showed retention of the monocyte Siglec phenotype
[77]. This wide array of CD33-related siglec expression on monocytes and macrophages is
suggestive of a degree of functional redundancy exists between these siglecs however, the
specific expression profiles between cell types is indicative of specificity of function. More
recently, research has uncovered more functional information regarding CD33-related siglecs;
they may not just exert inhibitory responses through suppression of ITAM-dependent signals,
as over-expression of siglec-9 in Mϕs both inhibits the TLR-induced expression of the pro-
inflammatory cytokine, TNFα, but also induced the anti-inflammatory cytokine, IL-10 [78].
Again, as with other Mϕ receptors, the importance of a balance between positive and negative
signals within the immune system is paramount.
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FcγRs: are a family of receptors which bind the Fc region of IgG/IgG immune complexes and
are responsible for mediating both activatory and suppressive responses by transducing their
ligand-binding signal through either an endogenous cytoplasmic ITAM or ITIM motif,
respectively. Three classes of FcγRs are expressed on immune cells such as Mϕs, these include
the high affinity FcγRI (CD64) which binds monomeric IgG and the low affinity receptors
FcγRII (CD32) and FcγRIII (CD16) that bind IgG immune complexes. Activatory receptors
which possess cytoplasmic ITAM sequences include FcγRIIIa, FcγRI and FcγRIIa whereas the
CD32 subtype, FcγRIIb is suppressive, containing a cytoplasmic ITIM sequence (reviewed in
[79]). Thus recognition and clearance of IgG immune complexes may induce either an
activatory or inhibitory signal which is dependent on expression profile of these FcRs and
potential cross-talk with other PRRs. Ligation of FcγRIIIa induces the expression and secretion
of Mϕ-derived TNFα, the mechanism of production and activation of which has been found
to be associated with pathological inflammation [80]. Ligation of FcγRI however, was found
to reverse Mϕ pro-inflammatory responses [81]. Indeed, taking into consideration the format
of presentation of IgG, the immune response cell and their FcγR expression profile, Mϕs can
be activated or inhibited with respect to inflammatory responses; differential FcγR-driven
induction and suppression in collagen-induced arthritis model have resulted in this being
considered as a realistic therapeutic regimen in the treatment of RA [82]. The final thing to
consider with respect to FcγR-induced responses in Mϕs is the fact that these responses may
differ between M1 and M2 subsets and that these responses may be deviated by manipulation
of FcγR signalling or indeed exhibit suppression of inflammatory responses or manipulation
of functional plasticity. Manipulation of these Mϕ receptors would represent a realistic option
when considering their association with alternative activation, M2-like anti-inflammatory
Mϕs.
Other macrophage suppressive receptors: Two further immunosuppressive molecules that
control  Mϕ  functionality  which  are  worthy  of  consideration  are  CD200R  and  SIRPα
(CD172a); both members of the immunoglobulin superfamily (IgSF). CD172a interacts with
a  broadly  expressed  ligand,  CD47,  which  results  in  the  suppression  of  Mϕs  through
interaction with the tyrosine phosphatases, SHP1 and SHP2 [83] and reviewed in [84]). In
addition, this interaction is made more complex by the observation of bi-directionality of
signalling,  where  CD47 ligation  has  been  found to  selectively  suppress  monocyte  IL-12
production, whereas TNFα, IL-1 and IL-6 was not suppressed. In contrast, the immunosup‐
pressive cytokines, TGFβ and IL-10, were not altered by CD47 ligation; suppression of IL-12
was  independent  of  TGFβ  and  IL-10  [85].  Thus,  molecules  such  as  CD172a  and  CD47
represent an attractive target couple for multi-mechanistic immune suppression. CD200R
ligation, on the other hand, transduces a simpler immunological signal. CD200 (OX-2) is a
cell surface glycoprotein containing Ig-like domains that interacts with CD200R expressed
on Mϕs [86]. The human homologue of CD200R was characterised by Wright and collea‐
gues who found that its cytoplasmic domain contained known signalling motifs [87]. The
role  of  CD200R  ligation  was  appreciated  to  be  potentially  suppressive  where  CD200-
deficient  mice  were  shown  to  display  increased  susceptibility  to  autoimmune  disease
models affecting joints. In accordance with this study, CD200Fc fusion protein was found
to exhibit beneficial immunomodulation of arthritis and allograft rejection [88,89]. Indeed,
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the CD200Fc anti-arthritic  response targeted pro-inflammatory cytokines in murine CIA,
suppressing  mRNA  gene  expression  of  TNFα,  IL-1β,  MMP13  but  also  IL-10  [90].  It  is
probable  that  CD200R represents  a  family  of  closely-related receptors;  four  homologues
exist in the mouse, two of which, however, may exhibit activatory properties rather than
suppressive, as they have been shown to pair with an ITAM-containing adaptor protein
DAP12  [87].  Considering  these  early  observations,  it  is  likely  that  such  IgSF  members
represent realistic therapeutic targets for immune suppression, activation and deviation of
Mϕ-mediated  pathological  mechanisms  associated  with  cancer,  transplantation  and
inflammation.
Cytokine expression and responsiveness: Dysregulation and aberrant functionality of Mϕs
is widely associated with pathology. Macrophages are central to phagocytosis and the
modulation of inflammatory responses, through the induction and regulation of cytokine
expression. Mϕs not only phagocytose pathogens and particulate material, they are important
for the clearance of dead and dying host cells, utilising a wealth of scavenger receptors such
as SRA, CD36, CD68, integrins, CD14, complement components and the phosphatidyl serine
receptor (reviewed in [91]). Clearance of necrotic host cell material is generally associated with
the induction of inflammatory responses, where necrotic cells are recognised by Mϕs and
result in the production of TNFα and the driving of Th1-mediated immune responses. In
contrast, Mϕs recognise apoptotic cells [92], resulting in an anti-inflammatory environment,
characterised by the production of TGFβ, PGE2 [93] and IL-10 [94]. In fact, the defective
clearance of apoptotic cells has been linked with autoimmunity [95]. Recognition of apoptotic
cells is thus important in immunoregulation modulated by Mϕs. Mϕs recognise and distin‐
guish between apoptotic and necrotic cells via danger-associated molecular patterns (DAMPs)
and apoptotic cell-associated molecular patterns (ACAMPs). This dichotomy in responsive‐
ness is reflective of Mϕ subset functionality; indeed M2-like, alternatively activated Mϕs
express a wide array of receptors for ACAMPs; it is likely that recognition of apoptotic cells
will activate and programme M2 cells towards an anti-inflammatory and regulatory pheno‐
type, whereas DAMPs and necrotic cells drive an immune activatory, pro-inflammatory
response (reviewed in [96]).
Cytokines are not only induced by phagocytic recognition and clearance of dead and dying
cells. They are produced by Mϕs and a wide variety of other immune cells as part of immune
activatory or regulatory responses. As such, Mϕs are modulated by a variety of cytokines; the
predominant Mϕ-modulatory cytokines include TGFβ, IL-10, IL-12, IL-4/IL-13, IFNγ and
TNFα. IL-4/IL-13 and TGFβ/IL-10 have been described above to be associated with priming
M2 Mϕ subset polarisation (M2a and M2c, respectively); whereas IL-12 and IFNγ play an
important role in the polarisation and functionality of M1 cells and concomitantly, suppressing
development and activation/functionality of M2s. The relative expression of these cytokines
is thus imperative to subset functionality and cross-regulation.
TGFβ and IL-10 modulate Mϕ polarisation and functional plasticity to that of an M2c subset
which exhibits a characteristic cytokine phenotype of IL-10hi, IL-12lo, IL-23lo and TGFβ+which
is associated with anti-inflammatory responses, scavenging, immunoregulation, tissue repair
and tumour promotion. Both TGFβ and IL-10 directly suppress immune activation via the
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down-regulation of the expression of MHC II, B7 costimulation (suppressing APC function)
and pro-inflammatory cytokine production, with an indirect effect through cross-regulation
of M1-derived cytokines and functionality. In contrast to this TGFβ-mediated suppression of
Mϕ-driven functionality, pro-inflammatory cytokines such as TNFα modulate M1-driven
responses, favouring anti-microbial killing, CMI and tissue-destructive pro-inflammatory
responses. TNFα activates Mϕs following IFNγ priming, which results in a strong activation
of NFκB and enhanced cell migration to inflammatory sites and consequent iNOS-mediated
anti-microbial killing [97]. It also primes a sustained inflammatory response [98] and Mϕ
survival, important to inflammation and to the pathology of sepsis [99]. TNFα and other pro-
inflammatory cytokines such as IL-1β, not only play a pivotal role in the initiation and
maintenance of the inflammatory response, but also modulate immunosuppressive mecha‐
nisms through the process of Mϕ endotoxin tolerance. Thus, the state of Mϕ activation,
polarisation of subset functionality and the relative contribution of activatory, suppressive and
immune-deviation signals associated with Mϕs, is of paramount importance in determining
an appropriate immune response or pathological response as a consequence on Mϕ immune
dysfunction (refer to figure 2 below). Finally, one last consideration regarding Mϕ functional
responses to cytokines is that responsiveness has been demonstrated to be dysregulated,
especially, with regards anti-inflammatory IL-10 signal transduction by IL-10 receptors in a
chronic inflammatory environment [100]. Consideration of cytokine responsiveness of Mϕs
can only be realistically appreciated when considering the local environment; homeostatic or
pathogenic!
Macrophage functionality and inflammatory pathology: Mϕs are particularly abundant in
mucosal tissues such as the oral cavity and the gastro-intestinal tract. Dysregulation of Mϕ
functionality in such mucosal tissue has been shown to have grave impacts on mucosal
function and to result in Mϕ-driven pathology. This section will focus on Mϕ dysregulation
and impact on host tissue in the context of M1-and M2-driven responses associated with oral
(chronic periodontitis and oral squamous cell carcinoma) and the GIT (Crohn’s disease,
ulcerative colitis and colorectal cancer) mucosal pathology. These pathologies display
pathological mechanisms aligned to M1-or M2-like functional phenotypes; to fully appreciate
these dysregulated responses, it is imperative to appreciate the functional phenotype of
healthy, homeostatic mucosal macrophages. From studies focussing on the characterisation of
gut mucosal Mϕs, in general mucosal Mϕs exhibit a functional phenotype similar to M2 Mϕs.
Intestinal Mϕs express phagocytic scavenger receptors (CD33, CD36, CD68), HLA-DR,
immunoregulatory receptors (CD200R and TGFβRI/RII) and immunoregulatory cytokines
(IL-10, TGFβ) whereas fail to express the co-stimulatory molecules (CD40, CD80, CD86),
pattern recognition receptors (CD14, TLRs), TREM-1, FcRs, CRs and the pro-inflammatory
cytokines (TNFα, IL-1β, IL-6, IL-18). On the other hand, in general, inflammatory Mϕs express
a wide variety of functional markers which include: PRRs (CD14, TLR2, TLR4, TLR5), FcRs
(CD16, CD32, CD64, CD89), CRs, HLA-DR, co-stimulatory molecules, chemokine receptors
(CCR5, CXCR4) and pro-inflammatory cytokines/markers (TREM-1, TNFα, IL-1β, IL-6, IL-18,
CCL20) [28,101-103].




Crohn’s disease (CD) is an inflammatory bowel disease (IBD) characterised by tissue-destruc‐
tive transmural inflammatory skip lesions which present along the whole length of the GI tract.
CD is characterised by dysfunctional innate immune responses, which result in a Th1/Th17 axis
of inflammatory destruction. This granulomatous inflammation is characterised by high
expression of IL-12/IL-23, resulting in the predominance of Th1/Th17 cells that produce IFNγ,
TNFα and IL-17 [104]. This dysregulated pro-inflammatory response is believed to be associ‐
ated with mutations to PRRs and pathogen sensing ability of the innate immune system.
Genetic mutations in the CARD15 gene which encodes NOD2, an intracellular sensing receptor
for bacterial peptidoglycan, are associated with CD Mϕs and have been demonstrated to
modulate NFκB activation and up-regulate expression of the pro-inflammatory cytokines
TNFα, IL-1β and IL-12 [105], whereas NOD2 activation would normally mediate anti-
Figure 2. Macrophage effector functionality is determined by a variety of activation, suppression and deviation. Mϕ
effector responses can be positively initiated by a range of receptors (yellow box) which include CLRs, TLRs, NLRs and
complement receptors (CRs) which induce a range of activatory signalling pathways (p38, ERK and JNK mitogen acti‐
vated protein kinases, MAPKs, and NFκB), resulting in specific gene expression. These positive signals can be sup‐
pressed (purple box) by a range of exogenous (SIGIRR, ST2, Siglecs, FcγRIIb, CD200R, SIRP-1α, TGFβR, IL-10R) and
endogenous signals (SOCS3, MKP-1, PI3K, ITIM-associated SHP-1, SHP-2, SHIP-1). Finally, Mϕ functionality can deviate
between M1 and M2 phenotype (white box), determined by exogenous factors (IL-4, IL-13, M-CSF, IFNγ, GM-CSF,
TGFβ, IL-10) and internal signalling molecules (STAT1, STAT6, p65 NFκB, p50 NFκB).
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inflammatory signals induced through TLR2 [106]. In addition, NOD2 mutation also results
in impaired recruitment of monocytes to mucosal tissue and their differentiation to a homeo‐
static intestinal Mϕ phenotype as well as impairment of Treg activity [107]. Thus, the combi‐
nation of a dysregulated innate response in favour of pro-inflammatory cytokines, aberrant
anti-inflammatory mechanisms, coupled with adaptive immune system bias towards a Th1/
Th17 cell mediated inflammatory response, result in the breaking of mucosal immune tolerance
in favour of the tissue-destructive inflammatory mechanisms observed in the pathology of
Crohn’s disease and its perpetuation by both pathogenic and commensal luminal contents
(reviewed in [108]). This loss in regulation results in a mucosal environment that is IL-10low
IL-12high, which induces M1-like Mϕ activation/differentiation and the up-regulation of
expression of pro-inflammatory cytokines and co-stimulatory molecules [109].
The oral mucosa plays a significant role in tolerance induction; it is thought that dysregulation
of mucosal Mϕ functionality contributes to the breaking of this tolerance and drives oral
inflammatory pathologies such as oral lichen planus, recurrent aphthous stomatitis and
chronic periodontitis [110]. Chronic periodontitis (CP) is a persistent inflammatory condition
of the periodontal tissue, characterised by bouts of relapse and remission that, if left untreated,
could result in destruction of periodontium and tooth loss. CP results from activation of host
inflammatory response as a consequence of constant microbial challenge mounted to a
dysbiotic microbial population present in the oral cavity, of which Porphyromonas gingivalis
(PG) is a prominent member [111,112]. PG is an intracellular oral pathogen, which invades oral
epithelial cells, dendritic cells and macrophages; clearance of such would require a Th1-
dependent cell mediated response [113,114]. PG-LPS subverts both host innate and adaptive
responses away from clearing responses by low endotoxin activity along with preferential
utilisation of TLR2 rather than TLR4 and by inducing Th2-dependent humoral responses,
respectively [115,116]. There is a dense population of Mϕs in the oral mucosa which react to
PG by producing large amounts of pro-inflammatory cytokines (TNFα, IL-1α, IL-1β, IL-6, IL-8,
IL-12, IL-18, IL-32, MCP-1) at the expense of anti-inflammatory cytokines (IL-10) [117];
displaying an M1 phenotype. What is a cause for concern, is that PG induces an M1-like
response whereas deviates the adaptive response to one of a non-clearing Th2-humoral
response. This, coupled with the fact that PG differentially induces endotoxin tolerance in M1
and M2-like Mϕs [54], presents scientists with real problems with regards utilising Mϕs as
therapeutic targets for the treatment of CP.
Less complicated is oral lichen planus (OLP); an inflammatory condition presenting as white
striations or plaques in the buccal mucosa, tongue and gingiva [118]. This pathology is
characterised by a dense T cell infiltrate with a corresponding destruction of basal membrane
and recruited monocytes, which display an M1 cytokine expression phenotype, with high
levels of GM-CSF, TNFα and IFNγ produced at the site of inflammation [118,119]. T cells
associated with OLP have been described to produce IFNγ [120], as such, IFNγ can activate
CD8+cytotoxic T cells, NK cells and can feedback to activate M1 Mϕs and perpetuate their
inflammatory effector response. These Mϕs are situated close to the basal membrane and can
contribute to its inflammatory destruction, through the action of TNFα produced [121].
Therefore, M1 Mϕs drive the progression of OLP by activating a Th1-mediated inflammatory
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response and perpetuation/exacerbation of this immunopathological response through a
positive feedback mechanism.
3.2. M2-driven pathology
In contrast to CD, ulcerative colitis (UC or idiopathic proctocolitis) is an IBD where its site
of  involvement  is  confined to  the  large  bowel  (colon and rectum) and characterised by
ulcerations  in  the  mucosal  lining layer.  Patients  with  UC present  with  abdominal  pain,
bleeding  anaemia  and  dietary  restriction,  resulting  as  a  consequence  of  inflammatory
destruction  of  the  superficial  mucosal  layer,  which  is  possibly  driven  by  dysbiosis  or
inappropriate  recognition  and  responsiveness  to  commensal  gut  organisms  [122].  This
pathology is driven by a M2/Th2-mediated pathogenic mechanism resulting in a predomi‐
nance of Th2-derived IL-4, IL-5 and IL-13 cytokine production. These cytokines induce B
cell class switching and the production of IgE with the consequent activation of mast cells
and  eosonophils,  which  degranulate  toxic  components  upon  cross-linkage  of  IgE  and
initiation  of  an  ADCC response.  As  with  CD,  there  is  an  increase  in  monocyte  recruit‐
ment to the gut mucosa, where there is a high proportion of Mϕs expressing a less mature
phenotype that are CX3CR1+TLR2+CD33+[123]. These CX3CR1+Mϕs have been described to
suppress the severity of DSS-induced colitis and may represent a beneficial Mϕ subset with
respect to inflammatory pathology [124]. Manipulation of this Mϕ phenotype may represent
a realistic  approach in controlling this  M2/Th2-driven inflammation.  Thus there is  a real
need to characterise the inflammatory Mϕ subset which is involved in driving this disease.
One observation that informs the scientific community with respect to Mϕ involvement in
UC is the fact that CD1d-restricted type II NKTs induce colitis in mice [125]; it is proba‐
ble  that  CD1d+cells,  where CD1d expression has been reported to  be restricted to  Mϕs,
initiate or perpetuate this inflammatory pathology in humans. In addition to expression of
IL-4, IL-13 and TNFα, serum levels of IL-23 have been associated with severity of disease
in UC patients [126]; whereas CD pathology involved an immune axis of M1/Th1/Th17, the
link with IL-23 production is suggestive of an M2/Th2/Th17 axis driving UC immunopatho‐
logical inflammation. In order for successful regimens to be adopted for the treatment of
UC, it is imperative that this immunopathological axis is further characterised with respect
to Mϕ functional phenotype and how these Mϕs can be modulated by expression analy‐
sis of both cell-associated immune activatory and suppressive molecules.
Macrophages have been realised to play a significant role in the immunopathology associated
with tumorigenesis and the progression of solid tumours. Tumour initiation and development
has been linked with NFκB activation and inflammation; indeed, it is now well established
that tumour associated macrophages (TAMs) exhibit a pro-tumoral, anti-inflammatory and
immunoregulatory M2 phenotype. As inflammation contributes to the progression of UC,
links have been suggested between UC (an M2/Th2 pathology) and the development of
colorectal cancer (CRC). Comparisons exist between UC and CRC with respect to the up-
regulation of both pro-inflammatory cytokines and the immunoregulatory cytokine, IL-10
[127], thus both pro-and anti-inflammatory mechanisms contribute to cancer progression.
With respect to Mϕ functionality, NFκB activation through classical or alternative activation
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pathways (p65 versus p50 NFκB) exhibit functional plasticity where TAMs display pro-
inflammatory, anti-tumoral M1-like responses or, conversely, anti-inflammatory, pro-tumoral
M2-like behaviour [128].
In the case of oral mucosa, M1-driven chronic inflammatory pathology such as OLP and the
resulting pro-inflammatory and anti-microbial environment (ROS/RNS) can induce mutagen‐
esis and malignant transformation of oral epithelial cells resulting in oral cancer. One such oral
cancer is oral squamous cell carcinoma (OSCC), characterised by a significant leukocyte
infiltration of lymphocytes and particularly monocytes, recruited by MCP-1, which become
TAMs [129]. These TAMs, facilitated by priming factors, such as M-CSF and IL-10, secreted by
cancer cells, develop a pro-tumoral M2 phenotype (IL-10, EGF, FGF, PDGF, VEGF)[130]
resulting in advanced stages of tumour progression [131,132]. This M2-like effector phenotype
of TAMs results in an immunosuppressive, anti-inflammatory and tissue reparative environ‐
ment, which benefits tumour growth. In addition to suppressing pro-inflammatory cytokines,
activation of anti-tumour T cell responses through APC function is suppressed as the expres‐
sion of MHC molecules is down-regulated and inhibitory co-stimulatory molecules, such as
B7-H4, are up-regulated [133-135]. Finally, the M2 cytokines, IL-10 and TGFβ, can induce
Tregs, which further strengthen the suppression of host anti-tumour responses [136]. Thus,
TAMs modulate cancer cell survival/growth whereas the environment presented by the
tumour cells influences the functional plasticity of the TAMs and that, through the bi-
directionality of cellular interactions, it may be possible for the TAM plasticity to be harnessed
in the control of tumour cell growth and even initiate tumour resolution.
4. Conclusions and future perspectives
Macrophages offer attractive drug targets for the treatment of a wealth of Mϕ-mediated
diseases of the oral and gastrointestinal mucosa. The role of Mϕs in driving inflammato‐
ry diseases such as CD, OLP, CP, UC, and cancer (CRC and OSCC) is being extensively
researched. With their role in the immunopathogenic mechanisms of these diseases, Mϕs
are  now a  realistic  candidate  for  “re-education”  of  their  functional  responses;  either  by
immune activation, suppression or deviation. Mϕs exhibit  pathogenic responses via M1-
functionality, as is the case in CD, OLP and CP, whereas M2 effector phenotype drives UC,
CRC and OSCC.  These pathogenic  immune cells  express  a  wealth of  immunoactivatory
receptors (TLRs, NLRs, RLRs, CLRs, FcRs, SRs and cytokine receptors) and, as such, can
be  induced  to  exhibit  pro-inflammatory  responses,  anti-inflammatory  responses,  anti-
microbial killing responses as well as antigen processing and presentation, hence priming
humoral and CMI adaptive responses against extracellular and intracellular pathogens. In
addition, they also express immunosuppressive molecules (exogenous and endogenous PRR
inhibitors, FcγRIIb, CD200R, SIRP-1α, Siglecs, NLR splice variants, IL-10, TGFβ) and may
exhibit a sensitivity to endotoxin tolerance. Finally, Mϕs also possess receptors/molecules
by which immune responses may be modulated or deviated; through FcRs, IL-4/IL-13/M-
CSF/IL-10 and IFNγ/GM-CSF to the benefit of the host. Future aims of manipulating Mϕ
effector functionality would focus on activation of M1 Mϕs to produce anti-tumour and
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pro-inflammatory cytokines, hence fostering a hostile anti-tumour innate environment as
well as priming adaptive anti-tumour responses for the treatment of colorectal cancer and
oral squamous cell  carcinoma. In addition to immune activation of anti-tumour respons‐
es, harnessing immune receptors for immune deviation would appear to be a potentially
effective approach;  whereby the functional  plasticity of  M2-like TAMs was manipulated
and re-programmed to a more anti-tumour setting by encouraging deviation of response
to be M1-directed [137]. Although translatability of these approaches has proved, as yet,
unsuccessful, this activation and re-programming approach has been appreciated for quite
some time [138,139].
With the similarity and connectivity between cancer and inflammation,  it  would appear
reasonable to use similar Mϕ-modulation approaches to the treatment of mucosal inflamma‐
tory pathology. With respect to CD, OLP and CP, the M1-driven pathologies,  Mϕ-based
immunotherapy is likely to focus on approaches that either suppresses, induce tolerance or
deviate a response by encouraging a redressing of the balance between M1/M2 by immune-
deviation towards an M2-driven response.  Such a  change towards M2 functionality  can
potentially  be  activated  through  M2-biassed  signals  through  scavenger  receptors  or
deviation via IC-FcγR, M-CSF or IL-4/IL-13 polarisation signals. More recently, this immune
deviation can be encouraged by the introduction of  products  derived from M2-skewing
extracellular pathogens such as helminth worms; the potential for medicine to travel full
circle  back to  a  more  sophisticated look at  old  therapies!  Finally,  these  destructive  M1-
driven  inflammatory  pathologies  may  warrant  suppression.  This  can  be  achieved  by
manipulating  mechanisms  and  molecules  associated  with  endotoxin  tolerance  through
chronic reception of pro-inflammatory cytokines or PAMPs through TLRs and through the
induction of a range of intracellular negative regulators such as Tollip, SHP-1, SHIP1, p50
NFκB, PI3K, as well as extracellular/membrane-bound regulators (CD200R, SIRP-1α, ST-2,
SIGIRR, IL-10R and TGFβR).
Through the presentation of the complex field of Mϕ biology with respect to Mϕ subsets;
priming of monocytes through defined differentiation pathways, Mϕ effector phenotype and
functional plasticity can be potentially manipulated in our favour for the treatment of M1-
driven and M2-driven pathology. The future therapeutic regimens which focus on macro‐
phage functionality in CD, OLP, CP, UC, CRC and OSCC can only hope to be successful from
considering total Mϕ functionality with respect to immune activation, suppression and
deviation.
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